pubmed.ncbi.nlm.nih.gov

Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer - PubMed

  • ️Tue Jan 01 2013

Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer

Rong Hu et al. EPMA J. 2013.

Abstract

Cancer is a complex disease that causes the alterations in the levels of gene, RNA, protein and metabolite. With the development of genomics, transcriptomics, proteomics and metabolomic techniques, the characterisation of key mutations and molecular pathways responsible for tumour progression has led to the identification of a large number of potential targets. The increasing understanding of molecular carcinogenesis has begun to change paradigms in oncology from traditional single-factor strategy to multi-parameter systematic strategy. The therapeutic model of cancer has changed from adopting the general radiotherapy and chemotherapy to personalised strategy. The development of predictive, preventive and personalised medicine (PPPM) will allow prediction of response with substantially increased accuracy, stratification of particular patient groups and eventual personalisation of medicine. The PPPM will change the approach to tumour diseases from a systematic and comprehensive point of view in the future. Patients will be treated according to the specific molecular profiles that are found in the individual tumour tissue and preferentially with targeted substances, if available.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Personalised (or individualised) variations are involved in each aspect of healthcare.

Figure 2
Figure 2

The contributions of ‘omics’ and systems biology to the practice of PPPM.

Figure 3
Figure 3

Analysis of comparative proteomics vs. comparative transcriptomics in human nonfunctional pituitary adenomas. *Comparative proteomics found 251 differential gel-spots, 93 differential gel-spots were excised for MS characterisation, and 56 proteins were identified.

Figure 4
Figure 4

Targeted organs that are used to analyse proteomic variations in human nonfunctional pituitary adenomas.

Figure 5
Figure 5

Techniques that are used to measure proteomic variations.

Figure 6
Figure 6

Techniques that are used to measure body fluid protein/peptide pattern variation.

Figure 7
Figure 7

To realise PPPM is a systematic engineering and needs multiple supports.

Similar articles

Cited by

References

    1. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191–1308. - PubMed
    1. Pollack IF. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. Neurosurg Pediatr. 2011;8:135–148. doi: 10.3171/2011.5.PEDS1178. - DOI - PubMed
    1. Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M. The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer. 2012;19:R131–R147. doi: 10.1530/ERC-11-0354. - DOI - PubMed
    1. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147:992–1009. doi: 10.1016/j.cell.2011.11.016. - DOI - PubMed
    1. Kang M, Buckley YM, Lowe AJ. Testing the role of genetic factors across multiple independent invasions of the shrub Scotch broom (Cytisus scoparius) Mol Ecol. 2007;16:4662–4673. doi: 10.1111/j.1365-294X.2007.03536.x. - DOI - PubMed

LinkOut - more resources